FDA expected to Okay Pfizer vaccine for teens
The US Food and Medication Administration is likely to authorize Pfizer's COVID-19 vaccine for youngsters ages 12 to 15 by in a few days, according to a federal official and a person acquainted with the process, establishing shots for many prior to the beginning of the next school year. The announcement is set to come a month after the organization found that its shot, which is already authorized for those age 16 and older, as well provided protection for younger group.
The federal official, speaking on the condition of anonymity to preview the FDA's action, said the agency was likely to expand its emergency use authorization for Pfizer's two-dose vaccine by early in a few days, and perhaps even sooner. The individual familiar with the procedure, who spoke on state of anonymity to discuss internal matters, verified the timeline and added that it's predicted that the FDA will approve Pfizer's make use of by even younger children sometime this fall.
The FDA action will be accompanied by a gathering of a federal government vaccine advisory committee to discuss whether to recommend the shot for 12- to 15-year-olds. Pictures could begin following the Centers for Disease Control and Prevention adopts the committee's recommendation. Those guidelines could be completed in a matter of days.
The New York Times first reported on the expected timing for the authorization.Pfizer found in late March released preliminary benefits from a vaccine study of 2,260 U.S. volunteers ages 12 to 15, demonstrating there were no instances of COVID-19 among fully vaccinated adolescents weighed against 18 among those granted dummy shots.
